Zacks Analyst Blog Highlights: Cree, Inc., General Electric, B/E Aerospace, Honeywell and Anadys

http://www.profits.zacks.com/
CHICAGO--(Business Wire)--
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day
the Zacks Equity Research analysts discuss the latest news and events impacting
stocks and the financial markets. Stocks recently featured in the blog include:
Cree, Inc. (NASDAQ: CREE), General Electric (NYSE: GE), B/E Aerospace (NASDAQ:
BEAV), Honeywell (NYSE: HON) and Anadys (NASDAQ: ANDS).

Get the most recent insight from Zacks Equity Research with the free Profit from
the Pros newsletter: http://at.zacks.com/?id=4579

Here are highlights from Tuesday`s Analyst Blog:

CREE: The Lights Are On

The global movement to energy-efficient lighting is prompting lighting companies
and consumers to look at other options. Therefore, lighting will be the
strongest end market for Cree, Inc. (NASDAQ: CREE), likely followed by video
displays and notebooks. Yield improvements, higher capacity utilization, larger
wafers and offshore production will increasingly offset new product ramp up
costs. The LED market is hot in our opinion, and the LLF acquisition opens up
new opportunity.

With the signing of the energy bill in December 2007, the U.S. government has
decided to ban inefficient light bulbs by 2012. The energy efficiency standards
set by the government effectively do away with incandescent light bulbs as we
know them today. Although General Electric (NYSE: GE) has stated that it is
developing a more efficient bulb that will meet the efficiency standards, a
delay in development may actually put it out of the running.

B/E Aerospace Hits Turbulence

B/E Aerospace (NASDAQ: BEAV) reported Q1-09 results. Overall Sales of $523.7
million were up by 10.7% because of the July 28, 2008 acquisition of Honeywell`s
(NYSE: HON) Consumable Solutions (HCS) distribution business. However, on a
pro-forma basis (i.e., assuming HCS had been on-board last year), Overall Sales
were down 15.6%.

Further, on the same pro-forma basis, sales were down in all of BEAV`s Segments:
Consumables Management (the segment in which HCS is parked) was off 11.1% to
$239.4 million; Commercial Aircraft declined by 18.9% to $225.9 million; and
Business Jet was down 19.7 % to $58.4 million. However, it should be noted that
Consumables Management was up by 96.2% on an as-reported basis.

Anadys: Too Early for HCV Drug

ANA598 is Anadys` (NASDAQ: ANDS) lead anti-HCV (hepatitis C Virus) drug
candidate currently under phase I studies. The company`s share price got a boost
recently on its strong efficacy data from a phase Ib study.

Anadys presented the final antiviral and safety data from all three dose levels
(200, 400 and 800 mg bid) at the 44th annual meeting of the European Association
for the Study of the Liver (EASL) on April 23, 2009. The trial enrolled total 35
subjects. ANA598 treatment resulted in rapid and sustained reductions in HCV RNA
with median reductions at end of treatment (day 4) exceeding 2 log10 (>99%) at
all dose levels.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros
newsletter: http://at.zacks.com/?id=2649.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis
to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks.
Our analysts are organized by industry which gives them keen insights to
developments that affect company profits and stock performance. Recommendations
and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest
analysis from Zacks Equity Research. Subscribe to this free newsletter today:
http://at.zacks.com/?id=2677

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in
1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns
in stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking system;
the Zacks Rank, which continues to outperform the market by nearly a 3 to 1
margin. The best way to unlock the profitable stock recommendations and market
insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of Profitable
ideas GUARANTEED to be worth your time! Register for your free subscription to
Profit from the Pros at http://at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should
always research companies and securities before making any investments. Nothing
herein should be construed as an offer or solicitation to buy or sell any
security.

Zacks.com
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com

Copyright Business Wire 2009